Superior Planning, LLC’s ImmunityBio IBRX Stock Holding History

Superior Planning, LLC’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$85	Buy	+9	New	+$72	﹤0.01%	2096

Other funds holding IBRX

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Superior Planning, LLC's IBRX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in ImmunityBio (IBRX) in Q3 2026: 9 shares worth $85. The stake represents ﹤0.01% of the portfolio and ranks #2096 among its holdings.

266 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

Superior Planning, LLC held 9 shares of ImmunityBio worth $85 as of Q3 2026.
ImmunityBio was a new Superior Planning, LLC position in Q3 2026.
ImmunityBio made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #2096 holding.
266 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.